|Articles|March 15, 2020
Monograph Development: Why and When to Participate
Author(s)J. Mark Wiggins, Joseph A. Albanese
This article explores another proactive advocacy approach that a bio/pharmaceutical company may take through participation in the development of new and revised monographs in the various pharmacopoeias.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5